189 related articles for article (PubMed ID: 10779792)
1. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.
MacGill TC; MacGill RS; Casadevall A; Kozel TR
J Immunol; 2000 May; 164(9):4835-42. PubMed ID: 10779792
[TBL] [Abstract][Full Text] [Related]
2. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
Zaragoza O; Casadevall A
Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
[TBL] [Abstract][Full Text] [Related]
4. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
6. Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties.
Cordero RJ; Pontes B; Frases S; Nakouzi AS; Nimrichter L; Rodrigues ML; Viana NB; Casadevall A
J Immunol; 2013 Jan; 190(1):317-23. PubMed ID: 23233725
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.
Taborda CP; Casadevall A
J Immunol; 2001 Feb; 166(3):2100-7. PubMed ID: 11160261
[TBL] [Abstract][Full Text] [Related]
8. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
9. Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies.
MacGill TC; MacGill RS; Kozel TR
Infect Immun; 2001 Feb; 69(2):1189-91. PubMed ID: 11160020
[TBL] [Abstract][Full Text] [Related]
10. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.
Gates-Hollingsworth MA; Kozel TR
Mol Microbiol; 2009 Oct; 74(1):126-138. PubMed ID: 19758241
[TBL] [Abstract][Full Text] [Related]
12. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
McFadden DC; Casadevall A
J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans.
Mukherjee J; Cleare W; Casadevall A
J Immunol Methods; 1995 Jul; 184(1):139-43. PubMed ID: 7622865
[TBL] [Abstract][Full Text] [Related]
14. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
15. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.
Kozel TR; deJong BC; Grinsell MM; MacGill RS; Wall KK
Infect Immun; 1998 Apr; 66(4):1538-46. PubMed ID: 9529079
[TBL] [Abstract][Full Text] [Related]
16. Antibody interactions with the capsule of Cryptococcus neoformans.
Feldmesser M; Rivera J; Kress Y; Kozel TR; Casadevall A
Infect Immun; 2000 Jun; 68(6):3642-50. PubMed ID: 10816523
[TBL] [Abstract][Full Text] [Related]
17. Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.
Kozel TR; MacGill RS; Wall KK
Infect Immun; 1998 Apr; 66(4):1547-53. PubMed ID: 9529080
[TBL] [Abstract][Full Text] [Related]
18. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
19. Capsular polysaccharides of Cryptococcus neoformans.
Bhattacharjee AK; Bennett JE; Glaudemans CP
Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
[TBL] [Abstract][Full Text] [Related]
20. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.
Nussbaum G; Cleare W; Casadevall A; Scharff MD; Valadon P
J Exp Med; 1997 Feb; 185(4):685-94. PubMed ID: 9034147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]